Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

PCSK9 Patent Fight: Amgen Opposes Doctor Efforts To Keep Praluent On Market

27 Jan 2017

• By Brenda Sandburg

court house

Related Content

‘Between A Rock And A Hard Place,’ Court Issues Injunction To Halt Praluent Sales

06 Jan 2017

J.P. Morgan Notebook Day 1: PCSK9 Face-Off, Teva’s Slowed Growth, Merck’s Keytruda Wins, Lilly’s CDK4/6 Hopes And More

10 Jan 2017

Related Companies

Sanofi

Regeneron Pharmaceuticals, Inc.

Amgen, Inc.

Additional Topics

United States Policy Intellectual Property Legal Issues BioPharmaceutical

More from Legal & IP

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.